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Abstract
Purpose An observational clinical and molecular study was
designed to evaluate the effects of the administration of
recombinant human FSH on sperm DNA fragmentation in
men with a non-classical form of hypogonadotropic hypo-
gonadism and idiopathic oligoasthenoteratozoospermia.
Methods In the study were included 53 men with a non-
classical form of hypogonadotropic hypogonadism and idio-
pathic oligoasthenoteratozoospermia. In all patients, sperm
DNA fragmentation index (DFI), assessed by terminal deoxy-
nucleotidyl transferase-mediated deoxyuridine triphosphate
(dUTP) in situ DNA nick end-labelling (TUNEL) assay, was
evaluated before starting the treatment with 150 IU of recom-
binant human FSH, given three times a week for at least
3 months. Patients’ semen analysis and DNA fragmentation
index were re-evaluated after the 3-month treatment period.
Results After recombinant human FSH therapy, we did not
find any differences in terms of sperm count, motility and
morphology. The average DNA fragmentation index was
significantly reduced (21.15 vs 15.2, p<0.05), but we found
a significant reduction in patients with high basal DFI values
(>15 %), while no significant variation occurred in the
patients with DFI values ≤15 %.
Conclusions Recombinant human FSH administration
improves sperm DNA integrity in hypogonadotropic hypo-
gonadism and idiopathic oligoasthenoteratozoospermia men
with DNA fragmentation index value >15 % .
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Introduction
It is well known that sperm DNA quality has been recog-
nized as one of the most important markers of male repro-
ductive potential [30, 42, 60], in contrast to standard semen
parameters such as sperm density, motility and morphology
that do not act as powerful discriminators between fertile
and infertile men [14, 21].
DNA damage in the male germ line is a major contributor
to infertility, miscarriage and birth defects in the offspring [2].
In animal models, it has been unequivocally demonstrated that
the genetic integrity of the male germ line plays a major role in
determining the normality of embryonic development [1].
In humans, several papers reported conflictual data
concerning the effects of higher DFI on ICSI clinical out-
comes. Morris et al. [39] showed that sperm DNA damage is
associated with impaired embryo cleavage. Increased DFI
seems to be associated with an higher miscarriage rates [14]
and also with a significantly increased risk of pregnancy loss
after in vitro fertilization (IVF) and intracytoplasmic sperm
injection (ICSI) [67]. A reduced DFI seems to be related to
increased ICSI outcomes [17, 33], other authors reported any
interference of DFI on clinical outcomes [32, 66].
In particular, chances for pregnancy are close to zero if
more than 30 % of spermatozoa present DNA fragmentation,
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either by means of natural conception or intrauterine insemi-
nation [7, 57]. In addition, Greco et al. in 2005 reported a
clinical pregnancy rate (PR) of 0 % with microinjection of
testicular sperm in patients with DNA fragmentation levels in
semen >15 %, as measured by TdTmediated-dUTP nick-end
labeling (TUNEL) [19]. Higher percentage of fragmented
chromatin in a seminal sample is associated with a reduced
pregnancy and implantation rates after conventional IVF and
it is predictive of failure of embryo development in couples
undergoing ICSI cycles [17] confirming the “paternal effect”
of sperm DNA on the embryo development, as demonstrated
by several other authors [10, 41, 61].
Since there is a clear relationship between sperm DNA
damage and poor assisted reproduction technology (ART)
outcomes, efforts should be directed in developing treat-
ments to improve sperm DNA quality that could be intro-
duced into clinical use. Only a limited number of studies
examined potential treatments to reduce sperm DNA dam-
age and no therapy has been proven to be indicated in
reduction of sperm DNA fragmentation [44]. There is grow-
ing evidence supporting the use of antioxidant therapy to
improve DNA integrity [19], although many studies did not
support these observations [12, 38]; moreover, some authors
reported benefits using FSH administration but with
conflicting results [4].
For infertile males patients with severe oligoasthenoterato-
zoospermia ICSI can be performed, but single sperm selection
for oocyte microinjection is based on standard morphological
criteria that have limited power in the determination of its
embryogenic capacity [29], possibly because they cannot
provide information about DNA integrity and thus impairing
ICSI outcomes [3, 33]. In 2006, Berkovitz proposed a mor-
phological sperm selection method, hypothesing that the pres-
ence of vacuoles in the sperm head was associated with
chromatin alterations, demonstrating that high-magnification
sperm selection could improve ICSI clinical outcomes (preg-
nancy, implantation, delivery and birth rates) [6].
Apoptosis plays an important role in spermatogenesis.
It is indispensable in limiting the excessive germ cell
proliferation to a number that can be adequately supported
by Sertoli cells, thus ensuring normal spermatogenesis.
Moreover, apoptosis seems to be responsible for the se-
lective removal of abnormal or injured germ cells [51]. It
has been shown that when good-quality sperm cells are
exposed to oxidative stress, their removal is often trig-
gered by apoptosis [40]. However, sometimes apoptosis is
not able to completely destroy the damaged cells and
these may differentiate into sperm that is still able to
fertilize (abortive apoptosis) [51].
In the past few years our scientific interest has been
focused on FSH, as its ability to support spermatogenetic
process, and its role in controlling apoptosis in male germi-
nal epithelium is well known [63]. Furthermore, several
studies demonstrated that patients with FSH receptor or
FSH-β subunit mutations show a defective spermatogenesis
with different semen parameters alterations that can lead to a
reduced sperm competence in producing embryos with
higher implantation potential [43, 59].
Some studies demonstrated that in men with idiopathic
oligoastenozoospermia, exogenous administration of FSH
improves sperm structure [5, 58]. The efficacy of r-FSH
therapy in oligozoospermic men, aiming at improving other
sperm parameters such as motility, number and morphology,
is still debated and published data remain controversial [13,
15]. In addition, recombinant human FSH (r-FSH) adminis-
tration improves sperm DNA integrity in men with idiopath-
ic oligoasthenoteratozoospermia (iOAT) with increased
DNA fragmentation index (DFI) values [11]. Other studies,
the treatment with rFSH in combination with human chori-
onic gonadotropin (hCG) was proved to be effective in
stimulating spermatogenesis in gonadotropin-deficient men
[36, 56, 64].
An impairment of gonadotropin secretion and, therefore,
a reduced efficiency of spermatogenesis were reported to be
frequently associated with conditions different from the
classical causes of secondary hypogonadism. These condi-
tions (metabolic, endocrine and eating disorders, physical
exercise etc.) have been associated with a non-classical form
of hypogonadotropic hypogonadism (HH) called “function-
al” HH. Functional HH differs from the classical one by the
evidence that gonadotropin levels are in the low-normal
range, but it is inadequate for the testosterone levels, that
often are also in the low-normal range [28].
The aim of this observational study was to investigate the
effects of r-FSH administration on sperm DNA fragmenta-
tion of functional HH patients undergoing ICSI due to
normal/low levels of FSH and LH despite oligoastenozoo-




Fifty-three functional HH iOAT men, with a median age of
33.6±7.6 years, referred to our clinics because of fertility
problems after at least 2 years of natural attempts of conceiv-
ing, and undergoing rFSH therapy, were selected for the study.
The inclusion criteria were: sperm count of ≤15×106/ml, total
motility ≤40 %, normal morphology ≤4 %, normal BMI (20–
25 Kg/m2), low/normal plasma FSH (1–8 IU/L), LH(1–
8 IU/L), prolactin (2–12 mg/L), testosterone (3–10 ng/ml)
and inhibin B levels (50.0–250.0 pg/ml). Exclusion
criteria were: presence of cryptorchidism, varicocele, genital
infections, antisperm antibodies, Y chromosome micro
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deletions, karyotype abnormalities, CFTR gene mutations and
systemic diseases.
In all patients sperm DNA fragmentation was evaluated
prior to treatment with 150 IU of recombinant human FSH
(GONAL-f®, Merck Serono, Roma) three times a week for
at least 3 months. All patients included in this study declared
to have followed the treatment plane. Patients’ semen anal-
ysis and DNA fragmentation were re-evaluated after the 3-
month treatment period. The TUNEL test was conducted by
blinded investigators.
This protocol was approved by the institutional review
board of the Centre and all patients had previously given
informed consent for the study.
Semen analysis and preparation
A single semen analysis was performed before the begin-
ning and at the end of therapy, 90 days later. Semen samples,
obtained by masturbation after 2–5 days of sexual absti-
nence, were examined within 60 min of ejaculation, follow-
ing a 30’ of incubation at 37 °C to allow liquefaction.
Ejaculate volume, pH and sperm concentration, motility
and morphology were evaluated according to World Health
Organization guidelines [65].
All semen samples were prepared by swim-up after dilu-
tion in HTF medium supplemented with 5 % Human Serum
Albumine and centrifuged at 300 g for 5–7 min. Swim up
was performed stratifying 200 μl of HTF medium supple-
mented with 5 % of HSA on the pellets, and incubating for
30 min at 37 °C. The spermatozoa collected in the supernatant
were smeared on poly-L-lysine coated slides for fixation
before performing the TUNEL test to evaluate the DNA
Fragmentation Index (DFI).
Assessment of sperm DNA fragmentation by TUNEL
Sperm DNA fragmentation index (DFI) was assessed by
terminal deoxynucleotidyl transferase-mediated deoxyuri-
dine triphosphate (dUTP) in situ DNA nick end-labelling
(TUNEL) assay.
Briefly, spermatozoa were smeared on poly-L-lysine
coated slides, air dried and fixed with 3.7 % paraformalde-
hyde for 60 min. Then paraformaldehyde was removed and
PBS-glycine was added (0.1 M glycine in PBS and
0.3 mg/ml BSA), the spermatozoa were washed for 5 min
in PBS (137 mM NaCl, 2.68 mM KC1, 1.47 mM KH2PO4,
8.1 mM Na2HPO4) and permeated for 10 min on ice in
TRITON X100 0.1 % and sodium-citrate 0.1 % in PBS;
then, 3 washes were made using PBS for 5 min each at room
temperature. The spermatozoa were then incubated for
60 min at 37 °C in a humidified chamber in 50 μl of a
mixture containing 5 μl of nucleotide mix, 1 μl of TdT
enzyme, and 45 μl of Equilibration Buffer (DeadEnd™
Fluorometric Tunel System, Promega Italia srl).
Control samples were incubated with the same mixture
without the TdT enzyme (negative control) or pre-treated for
5 min with 100 μl of DNAse buffer, and then treated for
10 min with a DNAse buffer solution containing 10 unit/ml
of DNAse I (positive control).
Reaction was blocked with SSC 2X for 15 min. Three
5 min washes were carried out in PBS. The spermatozoa
were observed under a fluorescent microscope. Approxi-
mately 300 cells were counted and DFI was calculated as
a ratio of the total number of spermatozoa evaluated by
bright field and the positive TUNEL spermatozoa: an in-
creased sperm DFI was defined for values >15 %, while a
DFI ≤15 % was considered normal.
Statistical analysis
Data are expressed as mean ± SD and were analysed
using the paired t-test and chi-square as appropriate. A
p-value <0.05 was considered statistically significant.
Results
In the study we used an in situ TUNEL assay to detect
fragments of DNA in human spermatozoa of the 53 iOAT
patients before and after 3 months of treatment with r-FSH.
The fields of fixed semen samples on the slide were
analysed, after TUNEL assay, by fluorescence and light
microscopy and then recorded with the specific software
(NIS-Element BR 2.30, Nikon), which allowed us to capture
separately fluorescence images, light images and the com-
bination. The advantage of having these three images of the
same field is that it is possible to estimate the number of
cells with DNA fragmentation from the fluorescence
images, while the light images discriminates, for each field,
the spermatozoa from the other cells that could interfere in
calculating the apoptotic rate. It should be noted that the
fluorescent cells include both sperm cells and somatic cells
(leukocytes, epithelial cells, round spermatids) so that only
with the fluorescent microscopy associated to light micros-
copy it was possible to distinguish sperm apoptosis from
somatic cells DNA fragmentation. The merging allowed us
to realize a specific counting of spermatozoa and to observe,
at the same time, their morphology and the molecular dam-
age associated, so to perform a real statistical evaluation
limited to sperm cells only.
Our results showed that after 3 months of r-FSH treat-
ment, no significant differences were observed between
baseline and post therapy semen sample in the total patients
evaluated as far as sperm count (6.8×106/ml±4.9 vs. 7.1×
106/ml±3.4), total motility (21.2 %±11 vs. 20.4 %±12.3),
J Assist Reprod Genet (2013) 30:497–503 499
and normal morphology (3.6 %±0.2 vs. 3.4±0.2) were
concerned. However, the percentage of sperm DNA frag-
mentation in the total patients dropped from 21.15±9.3 to
15.2±7.7 (Table 1, p<0.05). Interestingly, if patients were
divided in two groups according to their basal level of DFI,
no statistical difference was found in sperm DFI for patients
(n=14) with a baseline DFI ≤15 % (10.5±4.2 vs. 11.4±4.5)
(Table 2), but an evident and statistically significant DFI
reduction in patients (n=39) with sperm baseline DFI value
>15 % was found (24.4±9.6 vs. 15.4±4.6) (Table 3). No
differences were found in the seminal parameters pre and
post therapy for the two group divided according to their
DFI baseline rate (Tables 2 and 3). In Fig. 1 the images of a
field of a seminal sample captured by light microscopy (A),
by fluorescent microscopy (B) and the merge of images (C),
are shown as an example.
Discussion
The present study shows that 90 days of rFSH adminis-
tration improves sperm DNA integrity, by reducing DFI
values in the group of patients with functional HH and
iOAT showing a baseline DFI >15. The origins of DNA
damage in the male germ line during either the production
or the transport of sperm cells are probably due to multi-
ple causes: (i) apoptosis during the process of spermato-
genesis; (ii) DNA strand breaks produced during the
remodelling of sperm chromatin in the process of sper-
matogenesis; (iii) post-testicular DNA fragmentation in-
duced, mainly by oxygen radicals, during sperm transport
through the seminiferous tubules and the epididymis; (iv)
DNA fragmentation induced by endogenous caspases and
endonucleases; (v) DNA damage induced by radiotherapy
and chemotherapy; and (vi) DNA damage induced by
environmental toxicants [49].
In particular, during spermatogenesis some strand breaks
are caused physiologically by topoisomerase to reduce the
torsional stresses that are created when DNA is condensed
and packaged in the sperm head, during the late phase of
differentiation [35, 50]. Normally, breaks are physiologically
reassembled before spermatozoa are released from germinal
epithelium [27], but, as a consequence of testicular injuries,
including heat, exposure to toxicant [26, 31, 34] radiation
[37], withdrawal of hormonal support [22, 55, 61], other
testicular pathologies [18] or life habits (smoke, drug use),
the repair process could be impaired, so that spermatozoa
show high levels of DNA damage [8, 49].
Post-testicular DNA fragmentation mainly induced by
oxygen radicals, seems to be the main cause of apoptosis
in human germ cells [2]. Mammalian spermatozoa seem to
be highly sensitive to free radical attack, with the conse-
quent induction of a lipid peroxidation process that disrupts
the integrity of the plasma membrane and impairs sperm
motility [24, 25]. Mitochondrial DNA is also particularly
vulnerable to free radical attack because it is essentially
unprotected [52]. All these processes greatly destabilize
the DNA structure and may ultimately result in the formation
of DNA strand breaks [2].
FSH seems to play a pivotal role in spermatogenesis and
in sperm DNA maturation process. FSH is a strong anti-
apoptotic factor and during seminiferous tubule maturation
its synergistic action with testosterone and estradiol support
germ cell survival, while estradiol alone has an inhibitory,
pro-apoptotic effect [63]. FSH is a key regulator of testis
function, required for the establishment of full complements
of Sertoli and germ cells during postnatal testis development
and for the maintenance of spermatogenesis in the adult.
FSH plays an important role in germ cell survival rather than
proliferation during the window between 14 and 18 days of
testicular development, which coincides with the cessation
of Sertoli cell proliferation and the onset of germ cell mei-
osis during the first wave of spermatogenesis. FSH suppres-
sion induces spermatogonial apoptosis predominantly via
Table 1 Seminal characteristic and DFI pre and post therapy in the 53
iOAT patients
N° patients: 53 Baseline Post therapy
Total sperm count (x106/ml) 6.8±4.9 7.1±3.4
Total motility (%) 21.2±11 20.4±12.3
Normal morphology (%) 3.6±0.2 3.4±0.2
DFI (%) 21.15±9.3a 15.2±7.7a
a p-value<0.05
Table 2 Seminal characteristic and DFI at baseline and post therapy in
patients with DFI ≤15 %
N° patients: 14 Baseline Post therapy
Total sperm count (x106/ml) 8.2±1.2 7.5±2.3
Total motility (%) 23.2±6.1 18.4±10.1
Normal morphology (%) 3.5±0.3 3.2±0.2
DFI (%) 10.5±4.2 11.4±4.5
Table 3 Seminal characteristic and DFI at baseline and post therapy in
patients with DFI >15 %
N° patients: 39 Baseline Post therapy
Total sperm count (x106/ml) 8.6±0.9 7.9±1.7
Total motility (%) 24.1±4.4 22.4±6.2
Normal morphology (%) 3.7 %±0.1 3.4±0.2
DFI (%) 24.4±9.6 a 15.4±4.6 a
a p-value<0.05
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the intrinsic pathway, while spermatocyte apoptosis occurs
via both the intrinsic and extrinsic pathways [45].
Tesarik and colleagues [62] evaluated caspase activity
and DNA integrity in germ cells within in-vitro cultured
segments of human seminiferous tubules after induction
of apoptosis by FSH or testosterone withdrawal. FSH
withdrawal increased the incidence of DNA fragmenta-
tion in spermatocytes and spermatids, in a caspase-
independent pathway.
Recently, Colacurci et al. [11] demonstrated that r-FSH
administration improves sperm DNA integrity in iOAT men
with increased DFI values, but other studies showed contro-
versial results [4, 9].
To investigate the effects of r-FSH administration on
sperm DNA fragmentation of functional HH and iOAT
patients undergoing ICSI, we compared DFI before and
after 90 days of FSH therapy. In order to demonstrate a
positive effect of the hormone in improving the late sper-
matogenesis process, we performed a method that simulta-
neously highlights the morphology and molecular damage
of spermatozoa.
Our findings suggest that r-FSH administration may im-
prove sperm DNA integrity in functional HH and iOAT men
with increased DFI values. The r-FSH treatment seems to be
more effective in the patient where baseline DFI was higher
than 15 %, while it seems to have no effect in those patients
showing a baseline DFI less than 15 %, according to the
recent paper by Colacurci et al. [11]. Differently from other
papers we calculated DFI using three images of the same
field (bright field, fluorescent and merge) so that we esti-
mated the number of cells discriminating, for each field, the
spermatozoa from the other cells that could interfere in the
calculation of the apoptotic rate.
The positive effects of r-FSH in functional HH patients
could be explained by a modified biological activity of en-
dogenous FSH, requiring the support of exogenous FSH. In
fact, it has been demonstrated that the presence of FSH recep-
tors polymorphisms and of FSH receptor defects might be
involved in some form of male infertility [46, 47, 53]. In
addition, it has been demonstrated that men with FSH receptor
mutations demonstrate variable spermatogenic activity, rang-
ing from oligospermia to normal sperm counts [54].
Thus, we can speculate that exogenous FSH could have a
positive role in controlling apoptosis and all the pathways
involved in the process of spermatogenesis.
Our data shows that r-FSH administration did not lead to
an improvement of semen parameters; the differences
emerging from analysis of the literature can, in part, be
justified by various factors, such as criteria adopted in the
selection of the patients, the interpretation of the seminal
parameters, the treatment dose and its length [16].
Reducing the apoptotic rate in a seminal sample means to
increase the probability, in an ICSI cycle, to inject sperm
showing chromatin integrity. Several papers demonstrated
increased clinical outcomes when sperm DFI is in a physi-
ological range [17, 33, 48]. Recently some tools have been
proposed to try to select, prior to perform ICSI, a mobile,
normo-morphologic sperm showing chromatin integrity, us-
ing hyaluronic acid–binding method based on the presence
of a hyaluronic acid receptor [23], sperm magnetic sorting
with annexin V microbeads based on apoptotic markers
such as the presence of externalized phosphatidylserine to
the surface membrane of spermatozoa [20], but none were
considered sensitive and specific.
In conclusion, in our experience, FSH acts as a strong anti-
apoptotic agent in reducing DNA fragmentation in functional
HH and iOAT patients without modifying the semen param-
eters, as sperm count motility and morphology. The therapy
may be a specific treatment for infertile male partners of
couples undergoing ICSI, specifically in the case that basal
DFI is higher than 15 %, reducing the percentage of sperma-
tozoa with DNA integrity anomalies, suggesting a positive
effect on the reproductive outcome. Further studies will need
to verify if the DFI reduction after r-FSH therapy increases
ICSI clinical outcomes and to investigate the specific apopto-
tic pathways involved in DNA fragmentation in human sperm,
as well as the membrane receptors and the molecular cascades
activate by exogenous FSH administrated.
Fig. 1 TUNEL assay on spermatozoa samples, images captured by
microscopy in the same field. Light image (a), fluorescent image
(green) (b), merge of images (c). Red arrowhead: abnormal sperm
(flattened head) with DNA fragmentation; Yellow arrowhead:
abnormal sperm (angled neck) with DNA integrity; Blue arrowhead:
morphologically normal sperm with DNA fragmentation; Black arrow-
head: other cell. Scale bar=30 μm
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